ArticlePloS one2025
Behavioral and genetic analysis of the effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in C. elegans.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The "dark magic mushroom" co-produces amatoxins and psilocybin.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Psychedelics show promise in treating depression, PTSD, and substance use disorder, prompting research into their mechanisms of action. Most studies use rodent models, but genetic tools can be challenging to apply in this approach. Invertebrate models, like C. elegans, offer a cost-effective alternative with short generation times and genetic tractability. This study examined the worm's response to the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) by assessing four serotonergic behaviors. Effects of DOI exposure on locomotion speed, swimming frequency, and egg-laying were undetectable, but DOI strongly inhibited feeding. Interestingly, this effect was independent of serotonin receptors, suggesting DOI may act through alternative pathways. These findings indicate that C. elegans can serve as a useful model for studying psychedelic drug effects, potentially revealing novel mechanisms beyond the serotonergic system. Further research could help clarify these pathways, improving our understanding of the therapeutic potential of psychedelics and refining their efficacy in treating neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.